Sanofi

NASDAQ:SNY

Drug Manufacturers - General

Healthcare
$47.12 -0.73%

-$0.31 today

Market cap
$113.15B
Beta
0.28
P/E (TTM)
8.5
EPS (TTM)
$8.60
Dividend yield
5.62%
52W Low $41.86High $52.68

Volume 2.32M

Average 2.78M

SNY EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

SanofiNASDAQ: SNY

EBITDA · Q2 FY2026 · quarter ended Jun 2026

EBITDA growth accelerates

Q2 FY2026 EBITDA of €4.04B rose 23.5% year over year, ahead of the +15.5% change in trailing-twelve-month EBITDA. Sequentially, it rose 48.7% from the prior quarter. Over 3 fiscal years it compounded at -2.6% a year.

Context

  • EBITDA amounted to 26.7% of revenue in FY2025, up 1.8 pp from a year earlier.
  • EBITDA increased in 1 of the last 3 fiscal years.

What to watch

Whether EBITDA reaches the consensus estimate from 9 analysts of €17.25B (+38.3%) for the fiscal year ending Dec 2026, a step up from the +13.1% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
€4.04B+48.7% QoQ
Last fiscal yearDec 2025
€12.48B+13.1% YoY
LTMJun 2026
€14.77B+15.5% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+23.5%+11.0%-12.5 pp
1 year+13.1%+38.3%+25.2 pp
3-year CAGR-2.6%+13.5%+16.1 pp
5-year CAGR+9.9%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

EUR · from the income statement

Latest · FY2025
12.48B EUR
Year-over-year change
+13.1%
4-year CAGR
+2.0%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How SNY compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +15.5% is the 3rd highest of 11, against a peer median of +3.4%.
  • EBITDA amounts to 30.2% of revenue for SNY, versus a peer median of 34.3%.
SNY Competitors
EBITDA for SNY and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NVONovo Nordisk A/SLTM Jun 2026DKK 180.91B DKK+4.7%+26.8%54.9%
LLYEli Lilly and CompanyLTM Jun 2026$43.3B USD+103.7%+54.1%54.4%
NVSNovartis AGLTM Jun 2026$22.26B USD-2.0%+16.1%40.0%
AZNAstraZeneca PLCLTM Sep 2026$21.37B USD+18.6%+29.7%34.4%
AMGNAmgen Inc.LTM Jun 2026$17.62B USD+10.8%+11.6%46.2%
BMYBristol-Myers Squibb CompanyLTM Jun 2026$16.82B USD+11.6%-7.5%34.2%
SNYSanofiLTM Jun 2026€14.77B EUR+15.5%-2.6%30.2%
MRKMerck & Co., Inc.LTM Jun 2026$13.93B USD-44.4%+9.9%21.0%
PFEPfizer Inc.LTM Jun 2026$13.49B USD-33.1%-25.8%21.2%
GSKGSK plcLTM Jun 2026£8.8B GBP+2.2%+6.5%26.5%
GILDGilead Sciences, Inc.LTM Jun 2026$1.33B USD-87.8%+15.3%4.4%
Peer median (excluding SNY) —+3.4%+13.4%34.3%

Competitors are the stored peer set for SNY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue39.18B40.56B41.62B44.29B46.72B
Cost of Revenue12.26B11.88B12.63B13.21B13.05B
Gross Profit26.92B28.68B28.99B31.08B33.67B
Gross Margin68.7%70.7%69.7%70.2%72.1%
Research & Development5.69B6.5B6.51B7.39B7.84B
Selling, General & Admin9.56B8.74B8.93B9.18B10.24B
Operating Expenses18.79B18.52B22.03B23.83B24.07B
Depreciation & Amortization3.35B3.11B4.43B3.59B5.68B
EBITDA11.54B13.51B11.39B11.03B12.48B
EBITDA Margin29.5%33.3%27.4%24.9%26.7%
Operating Income8.13B10.16B6.96B7.25B9.6B
Operating Margin20.7%25.1%16.7%16.4%20.5%
Interest Income3.13M168.96M530.5M457.53M331M
Interest Expense377.37M384.8M512.82M622.58M626M
Other Income / Expenses(289M)(170M)(845M)(494M)(3.58B)
Income Before Tax7.84B9.99B6.12B6.76B6.02B
Pre-Tax Margin20.0%24.6%14.7%15.3%12.9%
Income Tax Expense1.56B1.91B1.02B1.2B1.04B
Net Income6.22B8.37B5.4B5.56B7.81B
Net Margin15.9%20.6%13.0%12.6%16.7%
EPS (Basic)2.493.192.152.193.20
EPS (Diluted)2.493.182.152.193.20
Weighted Avg Shares2.51B2.5B2.5B2.5B2.44B
Weighted Avg Shares (Diluted)2.51B2.5B2.51B2.5B2.44B

Sanofi

NASDAQ:SNY

Intrinsic Alpha fair value

Locked

Current Price

$47.12

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.